Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis

[1]  E. Manheimer,et al.  Herbal medicines for treating HIV infection and AIDS. , 2005, The Cochrane database of systematic reviews.

[2]  G. Koren,et al.  Natural health product–HIV drug interactions: a systematic review , 2005, International journal of STD & AIDS.

[3]  Kelly H. Jordan,et al.  Coadministration of Milk Thistle and Indinavir in Healthy Subjects , 2003, Pharmacotherapy.

[4]  K. Gallicano,et al.  Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. , 2003, British journal of clinical pharmacology.

[5]  Jos H Beijnen,et al.  Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs , 2002, AIDS.

[6]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[7]  J. Falloon,et al.  Effect of Milk Thistle on the Pharmacokinetics of Indinavir in Healthy Volunteers , 2002, Pharmacotherapy.

[8]  J. Falloon,et al.  The effect of garlic supplements on the pharmacokinetics of saquinavir. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D L Sackett,et al.  Why randomized controlled trials fail but needn't: 2. Failure to employ physiological statistics, or the only formula a clinician-trialist is ever likely to need (or understand!). , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[10]  S. Khoo,et al.  P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? , 2001, AIDS.

[11]  J. Beijnen,et al.  Drug interaction between St John's wort and nevirapine. , 2001, AIDS.

[12]  S. Strom,et al.  Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[13]  U. Fuhr,et al.  Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. , 2000, Pharmacology & toxicology.

[14]  G R Wilkinson,et al.  Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[15]  J. Beijnen,et al.  Combination of Protease Inhibitors for the Treatment of HIV-1-Infected Patients: A Review of Pharmacokinetics and Clinical Experience , 2000, Antiviral therapy.

[16]  J. Falloon,et al.  Indinavir concentrations and St John's wort , 2000, The Lancet.

[17]  Kathleen M. Fairfield,et al.  Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. , 1998, Archives of internal medicine.

[18]  J. Lehmann,et al.  The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.